Cancer - Kidney(구연) Oral Session 5 / Cancer - Kidney (Ⅰ) (O-049) Grand Ballroom(2F) 11월28일(수) 14:00-15:00 First-line sunitinib을 치료받은 전이성 신장암환자에서 Sarcopenia가 예후에 미치는 영향 인제대학교 의과대학 비뇨의학과 교실¹ 부산대학교 의과대학 비뇨의학과 교실² 이찬호¹, 민권식¹, 김완석¹, 서원익¹, 박태용¹, 구자윤², 하홍구², 정재일¹ Purpose Sarcopenia is a critical physiological change during the development of cancer cachexia. We retrospectively investigated the prognostic role of sarcopenia in patents who treated with first-line sunitinib for clear-cell metastatic renal cell carcinoma (mRCC). Methods A total of 36 patients who received first-line sunitinib treatment were evaluated. Skeletal muscle index (SMI) was measured using pre-treatment computed tomography. Sarcopenia was assessed using sex-specific cut-offs for SMI that were adjusted for body mass index (BMI). Predictive values for time to treatment failure (TTF) and overall survival (OS) were assessed using the Cox proportional hazards regression model and the Kaplan-Meier method. Results The median follow-up of the cohort was 13.5 months after first-line sunitinib treatment. The median TTF and OS were and 8.25 and 12.4 months, respectively. A total of 14 (38.9%) patients were classified as having sarcopenia. In the Kaplan-Meier analysis, the median TTF and OS of patients with sarcopenia was significantly shorter than those without sarcopenia (2.3 vs. 11.8 months; p <0.001, 6.1 vs. 44.4; p <0.001, respectively). The multivariate analysis showed that sarcopenia was an independent prognostic indicator of TTF (HR, 6.69; 95% CI, 1.85-24.18; p =0.004) and OS (HR, 9.25; 95% CI, 2.07-41.36; p =0.004). Conclusion Sarcopenia is a significant prognostic factor in patients with clear-cell mRCC who are receiving first-line sunitinib treatment. keywords : metastatic RCC, Sarcopenia, Sunitinib